Vishal Sikri

Beckman Coulter, Inc. manufactures and distributes biomedical testing instrument systems and general biomedical research products. It develops and markets products that simplify, automate and innovate complex biomedical testing. The firm’s systems operate in both diagnostics and life sciences laboratories on seven continents. Its products improve the productivity of medical professionals and scientists, supplying critical information for improving patient health and delivering trusted solutions for research and discovery. The company was founded in 1935 by Arnold O. Beckman and is headquartered in Brea, CA.

inVentiv Health Clinical, Inc. provides clinical research and drug development services. It provides its services to the pharmaceutical, biotechnology, generic drug, and medical device industries. The firm offers clinical-development solutions including consulting services, Phase I clinical studies, bioequivalency and pharmacodynamic studies, bioanalytical analyses, and Phase II, III, and IV clinical development programs. The company was founded in 1984 and is headquartered in Princeton, NJ.

Cogenics Icoria, Inc. provides medical research services. The firm offers genomics and proteomics-related research instruments, consumables, data, including databases, software & other research-oriented products. Icoria offers gene expression analysis and other related services. Its tissue informatics software performs tissue analysis for toxicology studies of early-stage drug candidates and other purposes. The firm also provides biomarkers to develop diagnostics and therapies for liver injuries, metabolic conditions & cancer. The company is headquartered in Research Triangle Park, NC.

CommonSpirit Health is a non-profit organization, which engages in the provision of medical services and residential-living facilities. The firm offers in-house health care assistance services to patients who are undergoing rehabilitating treatment and managing chronic conditions. It also provides community cancer center programs, orthopedic care services, and financial assistance for patients. The company was founded in 1996 and is headquartered in Chicago, IL.

Ortho-Clinical Diagnostics, Inc. engages in the manufacture and design of diagnostic, transfusion, clinical equipment, and systems. It provides solutions for screening, diagnosing, monitoring, and confirming diseases early before they put lives at risk. Its products include instrument systems and reagents that screen for AIDS and hepatitis C, as well as blood typing systems. The company was founded in 1939 and is headquartered in Raritan, NJ.

University of Southern California is a private research university that mainly offers undergraduate, graduate & other higher education. The university was founded in 1880 and is headquartered in Los Angeles, CA.

AccentCare, Inc. engages in the provision of home health care services. Its services include personal care services, hospice care, private duty nursing, and care management. The company was founded by Scott Brogi, Robert Prosek, Joseph I. Davis, and Janet M. Biski and is headquartered in Dallas, TX.

Syneos Health LLC operates therapeutically focused global contract research organization. It provides pharma and biotech services. The firm specializes in the hematology, immunology and inflammation infectious diseases, oncology, ophthalmology, cardiovascular, CNS analgesia, CNS neurology, CNS psychiatry, endocrinology, and gastroenterology and hepatology. The company was founded by Kenneth A. Selzer in 1985 and is headquartered in Raleigh, NC.

Craig-Hallum Capital Group LLC (Craig-Hallum) is an employee-owned, idea-driven research, trading and investment banking firm headquartered in Minneapolis, Minnesota. The firm was founded by Bradley Baker and Kevin Harris in 1997. Craig-Hallum provides research, institutional sales and trading and investment banking services to institutional investors and growth companies.

Sosei R&D Ltd. manufactures pharmaceutical products. It develops and commercializes product opportunities based upon clinical uses for known drugs and templates. The company was founded by Julian Gilbert and Robin Bannister in March, 2000 and is located in Saffron Walden, the United Kingdom.

Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ.

AssureRx Health, Inc. operates as a personalized medicine company that develops genetic tests. It specializes in pharmacogenomics, a study of the genetic factors that influence an individual’s response to drug treatments, as well as evidence-based medicine and clinical pharmacology. The firm offers GeneSight, a genetic test that helps healthcare providers to take a personalized approach for prescribing medicine for patients; GeneSight Psychotropic, a test that analyzes genes that affects a patient’s response to antidepressant and antipsychotic medications; and GeneSight Analgesic, a test that analyzes how genes affect the way the body respond to medicines prescribed to treat acute or chronic pain. The company was founded by Donald R. Wright Jr. in 2006 and is headquartered in Mason, OH.

Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom.

Provista Diagnostics, Inc. operates as a diagnostic company. It focuses on the development and commercialization of proprietary blood based diagnostic, prognostic, and monitoring tests in women's cancer. Its products include videssa breast, ovarian, endometrial, and HPV associated. The company is headquartered in Alpharetta, GA.

Abcodia Ltd. engages in the validation and discovery of molecular biomarkers. The firm works alongside University College London and in partnership with diagnostic, pharmaceutical and technology companies to exploit a prospective serum bank for the purpose of ethical biomarker validation and discovery. The company was founded in 2010 and is headquartered in London, the United Kingdom.

KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom.

Allergan USA, Inc. manufactures and supplies pharmaceutical products. The firm's brand portfolio delivers treatments that address the medical need in various therapeutic categories that include dermatology and aesthetics; central nervous system; eye care; women’s health and urology; gastroenterology; and cardiovascular disease and infectious disease. The company was founded in June 2005 and is headquartered in Madison, NJ.

Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark.

Congenica Ltd. develops genome-based discovery and diagnostic technologies. It uses Sapientia technology platform, which allows genome scale DNA sequence data to be presented within a clinically actionable diagnostic report. The company was founded by Matthew Hurles, Richard Durbin and Philip Beales in 2013 and is headquartered in Hinxton, the United Kingdom.

Cambridge Innovation Capital Ltd (Cambridge Innovation Capital) is a venture capital firm founded in 2013. The firm is headquartered in Cambridge, United Kingdom.

Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom.

CMR Surgical Ltd. develops universal robotic system for minimal access surgery. The firm is presently evaluating the ability of the versius system to perform upper GI, gynaecological, colorectal and renal surgery in cadaveric trials. The company was founded by Martin Frost and Mark Slack in January 2014 and is headquartered in Cambridge, the United Kingdom.

Microbiotica Ltd. performs research and experimental development on biotechnology. The company was founded by Michael Anthony Romanos, Trevor David Lawley and Gordon Dougan in December 2016 and is headquartered in Cambridge, the United Kingdom.

Exvastat Ltd. operates as pharmaceutical company. The firm develops treatment for acute respiratory distress syndrome (ARDS) based on a repurposed drug which is marketed worldwide for other indications. The company was founded by David Cavalla , Charlotte Summers and Andrew McElroy in 2016 and is headquartered in Cambridge, the United Kingdom.

Petmedix Ltd. engages in developing therapeutics industry. It focuses on animal health by developing antibody therapeutics. The company was founded by Thomas Weaver and is headquartered in Cambridge, the United Kingdom.

Pretzel Therapeutics, Inc. is an American biotechnology company that develops therapies by utilizing mitochondrial biology. Pretzel Therapeutics is based in an undisclosed location and has research facilities in another undisclosed location. The company aims to develop treatments that address the genetic causes of mitochondrial dysfunction. The company was founded by academic experts in mitochondrial biology and is supported by a world-class investor syndicate. Jay Parrish has been the CEO of the company since 2021.